Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis.

Zhang, Haoyue; He, Yuying; Davies Forsman, Lina; Paues, Jakob; Werngren, Jim; Niward, Katarina; Schön, Thomas; Bruchfeld, Judith; Alffenaar, Jan-Willem; Hu, Yi

Zhang, Haoyue; He, Yuying; Davies Forsman, Lina; Paues, Jakob; Werngren, Jim; Niward, Katarina; Schön, Thomas; Bruchfeld, Judith; Alffenaar, Jan-Willem; Hu, Yi.

Afiliación

Zhang H; Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
He Y; Institute of Tuberculosis Control, Guizhou Provincial Center for Disease Control and Prevention, Guiyang, China.
Davies Forsman L; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
Paues J; Department of Medicine, Division of Infectious Diseases, Karolinska Institute, Stockholm, Sweden.
Werngren J; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Niward K; Department of Infectious Diseases, Linköping University Hospital, Linköping, Sweden.
Schön T; Department of Microbiology, The Public Health Agency of Sweden, Stockholm, Sweden.
Bruchfeld J; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
Alffenaar JW; Department of Infectious Diseases, Linköping University Hospital, Linköping, Sweden.
Hu Y; Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Front Pharmacol ; 13: 1032674, 2022.

Article en En | MEDLINE | ID: mdl-36699070

Palabras clave

dose evaluation; linezolid; multidrug-resistant tuberculosis; pharmacodynamics; pharmacokinetics

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google